Century Therapeutics made changes in its C-suite with the appointment of Morgan Conn as chief financial officer and Chad Cowen as chief scientific officer. Additionally, Hy Levitsky, who served as Century's president of research and development, will transition from operational duties to serve as an advisor.
Company Information
Company
Century Therapeutics
Location
1 BRIDGE PLAZA
Philadelphia, Pennsylvania, United States
About
Century Therapeutics (NASDAQ: IPSC) is harnessing the power of adult stem cells to develop curative cell therapy products for cancer that we believe will allow us to overcome the limitations of first-generation cell therapies. Our genetically engineered, iPSC-derived iNK and iT cell product candidates are designed to specifically target hematologic and solid tumor cancers. We are leveraging our expertise in cellular reprogramming, genetic engineering, and manufacturing to develop therapies with the potential to overcome many of the challenges inherent to cell therapy and provide a significant advantage over existing cell therapy technologies. We believe our commitment to developing off-the-shelf cell therapies will expand patient access and provide an unparalleled opportunity to advance the course of cancer care.
PhiladelphiaManufacturingBiotechnologyHealthcareHealth CareTherapeutics